natgillin/translations-raw huggingface dataset:
A Phase 1 interaction study evaluated the effect of cigarette smoking (CYP1A2 inducer) on the pharmacokinetics of Esbriet.
U ispitivanju interakcija faze 1 ocjenjivao se učinak pušenja cigareta (induktor CYP1A2) na farmakokinetiku lijeka Esbriet.
A phase 2 study of sunitinib was conducted in patients who were refractory to prior cytokine therapy with interleukin-2 or IFN-.
Provedeno je kliničko ispitivanje sunitiniba faze II u bolesnika koji nisu reagirali na prethodnu citokinsku terapiju interleukinom-2 ili IFN-α.
a Phase 3 dose optimisation study results reported at 2 year study follow up. b CA180-034 study results in recommended starting dose of 100 mg once daily. c CA180-035 study results in recommended starting dose of 140 mg once daily.
b Rezultati ispitivanja CA180-034 uz preporučenu početnu dozu od 100 mg jedanput dnevno. c Rezultati ispitivanja CA180-035 uz preporučenu početnu dozu od 140 mg jedanput dnevno.
a Phase 3 dose optimisation study results reported at the recommended starting dose of 140 mg once daily (n=304) population at 2 year final study follow up. b Includes ventricular dysfunction, cardiac failure, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and ventricular failure.
a Rezultati ispitivanja optimizacije doze faze 3 u populaciji liječenoj preporučenom početnom dozom od 140 mg jedanput dnevno (n=304) prijavljeni nakon 2 godine praćenja u sklopu ispitivanja. b Uključuje ventrikularnu disfunkciju, srčano zatajenje, kongestivno zatajenje srca, kardiomiopatiju, kongestivnu kardiomiopatiju, dijastoličku disfunkciju, smanjenje ejekcijske frakcije i zatajivanje ventrikula.
A phase 3, randomized, double-blind, placebo-controlled study of sunitinib was conducted in patients with GIST who were intolerant to, or had experienced disease progression during or following treatment with, imatinib (median maximum daily dose 800 mg).
Provedeno je randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje sunitiniba faze III u bolesnika s GIST-om koji nisu podnosili imatinib ili u kojih je došlo do progresije bolesti tijekom ili nakon liječenja imatinibom (medijan maksimalne dnevne doze 800 mg).
A phase 3, randomized, multi-centre international study evaluating the efficacy and safety of sunitinib compared with IFN- in treatment-naïve MRCC patients was conducted.
Provedeno je randomizirano, multicentrično, međunarodno ispitivanje faze III u svrhu procjene djelotvornosti i sigurnosti sunitiniba u usporedbi s IFN-α u bolesnika s metastatskim karcinomom bubrežnih stanica koji prethodno nisu bili liječeni.
A Phase 4 study was conducted to assess safety, efficacy, and pharmacokinetics of daptomycin in paediatric patients (1 to 17 years old, inclusive) with cSSTI caused by Gram-positive pathogens.
Provedena je faza 4 klinikog ispitivanja kako bi se ocijenila sigurnost, djelotvornost i farmakokinetika daptomicina u pedijatrijskih bolesnika (uključujući starosnu dob od 1 do 17 godina) s kompliciranom infekcijom kože i mekog tkiva uzrokovanom Gram pozitivnim patogenima.
A phase I dose-escalation study of oral sunitinib was conducted in 35 paediatric and young adult patients (aged 2-21) with refractory solid tumours, the majority of whom had a primary diagnosis of brain tumour.
Ispitivanje povećanja doze faze I za oralni sunitinib provedeno je na 35 pedijatrijskih i mlađih odraslih bolesnika (u dobi od 2-21) oboljelih od refraktornih solidnih tumora, od kojih je većina imala primarnu dijagnozu tumora na mozgu.
A phase I dose-escalation study of oral sunitinib was conducted in paediatric and young adult patients (aged 2-21) with refractory solid tumours, the majority of whom were enrolled with a primary diagnosis of brain tumour.
Ispitivanja povećanja doze faze I za oralni sunitinib provedeno je na pedijatrijskim i mlađim odraslim bolesnicima (u dobi od 2-21) oboljelim od refraktornih solidnih tumora, od kojih je većina uključena s primarnom dijagnozom tumora na mozgu.
A phase I study evaluating the effect of ketoconazole treatment (a potent CYP3A4 inhibitor) on vinflunine pharmacokinetics indicated that co-administration of ketoconazole (400 mg orally once daily for 8 days) resulted in a 30% and 50% increase in blood exposures to vinflunine and its metabolite 4Odeacetyl-vinflunine (DVFL), respectively.
Ispitivanje faze I kojim se procjenjivao učinak liječenja ketokonazolom (potentni inhibitor CYP3A4) na farmakokinetiku vinflunina pokazalo je da je istodobna primjena ketokonazola (400 mg oralno jedanput na dan tijekom 8 dana) za posljedicu imala 30%-tno i 50%-tno povećanje izloženosti vinfluninu u krvi, odnosno njegovu metabolitu 4Odeacetil-vinfluninu (DVFL).
A Phase I study was conducted to evaluate the PK of the components of Teysuno and their metabolites in cancer patients with impaired renal function compared to those with normal renal function.
Provedena je studija faze I za evaluaciju farmakokinetike sastojaka lijeka Teysuno i njegovih metabolita u bolesnika oboljelih od raka sa oštećenom bubrežnom funkcijom u usporedbi s bolesnicima sa normalnom bubrežnom funkcijom.
A phase II study examined dabigatran etexilate and warfarin in a total of 252 patients with recent mechanical valve replacement surgery (i.e. within the current hospital stay) and in patients who received a mechanical heart valve replacement more than three months ago.
U isptivanju faze II, dabigatraneteksilat i varfarin ispitani su na ukupno 252 bolesnika koji su bili nedavno podvrgnuti kirurškom zahvatu ugradnje mehaničkog zaliska (tj. u sklopu aktualne hospitalizacije) kao i u bolesnika koji su prošli postupak ugradnje mehaničkog srčanog zaliska prije više od tri mjeseca.
A phase II, randomised double-blind study of two dose levels (200 mg or 800 mg once daily) of Odomzo was conducted in 230 patients with either locally advanced basal cell carcinoma (laBCC) (n=194) or metastatic basal cell carcinoma (mBCC) (n=36).
Randomizirano, dvostruko slijepo ispitivanje faze II dviju razina doze (200 mg ili 800 mg jedanput na dan) Odomza provedeno je na 230 bolesnika ili s lokalno uznapredovalim karcinomom bazalnih stanica (luKBS) (n=194) ili metastatskim karcinomom bazalnih stanica (mKBS) (n=36).
A Phase IIb, placebo-controlled, double-blind, randomised trial (C208) evaluated the antibacterial activity, safety, and tolerability of SIRTURO in newly diagnosed patients with sputum smear-positive pulmonary MDRH&R- and pre-XDR-TB.
Placebom kontrolirano, dvostruko slijepo, randomizirano ispitivanje (C208) Faze IIb, procijenilo je antibakterijsko djelovanje, sigurnosti i podnošljivosti lijeka SIRTURO u novodijagnosticiranih bolesnika s razmazom sputuma pozitivnim na MDRH&R- i pre-XDR-TB.
A Phase III international, multicentre, open label, randomised, two-stage, three-arm clinical study (BO21004/CLL11) investigating the efficacy and safety of Gazyvaro plus chlorambucil (GClb) compared to rituximab plus chlorambucil (RClb) or chlorambucil (Clb) alone was conducted in patients with previously untreated chronic lymphocytic leukaemia with comorbidities.
Provedeno je međunarodno, multicentrično, otvoreno, randomizirano kliničko ispitivanje faze III, s dva stadija i tri skupine (BO21004/CLL), u kojem su ispitivane djelotvornost i sigurnost lijeka Gazyvaro u kombinaciji s klorambucilom (GClb) u usporedbi s rituksimabom i klorambucilom (RClb) ili samo klorambucilom (Clb) u bolesnika s prethodno neliječenom kroničnom limfocitnom leukemijom i komorbiditetima.
A phase III multicentre, randomised, blinded study was conducted to assess the safety and efficacy of pasireotide intramuscular use versus octreotide intramuscular use in medically naïve patients with active acromegaly.
Multicentrično, randomizirano, slijepo ispitivanje faze III bilo je provedeno da bi se ocijenila sigurnost i djelotvornost pasireotida primijenjenog intramuskularno u usporedbi s oktreotidom primijenjenim intramuskularno u bolesnika s aktivnom akromegalijom koji ranije nisu primali terapiju.
A phase III, multicentre, randomised study was conducted to evaluate the safety and efficacy of different dose levels of Signifor over a twelve-month treatment period in Cushing’s disease patients with persistent or recurrent disease or de novo patients for whom surgery was not indicated or who refused surgery.
Multicentrično, randomizirano ispitivanje faze III bilo je provedeno da bi se procijenila sigurnost i djelotvornost različitih doza Signifora tijekom razdoblja liječenja od 12 mjeseci kod bolesnika s perzistentnom ili rekurentnom Cushingovom bolešću, ili kod de novo bolesnika u kojih kirurški zahvat nije bio indiciran ili koji su odbili kirurški zahvat.
A physician’s guide to prescribing.
Vodič liječnicima za propisivanje.
A picture, known as a scan, can be taken.
Može se snimiti slika, takozvani sken.
a piece of gauze bandage or a sterile gauze swab, a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
komadić gaze ili sterilni štapić s gazom, neprobojni spremnik (plastični spremnik kojeg daje bolnica ili ljekarna) u koji na siguran način možete odložiti štrcaljke).
a piece of gauze bandage or a sterile gauze swab, a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
komadić gaze ili sterilni štapić s gazom, neprobojni spremnik (plastični spremnik kojeg daje bolnica ili ljekarna) u koji na siguran način možete odložiti štrcaljke.
a piece of gauze bandage or a sterile gauze swab, a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
mali povoj od gaze ili sterilna gaza, neprobojni spremnik (plastični spremnik koji se može nabaviti u bolnici ili ljekarni) tako da u njega možete na siguran način odložiti upotrijebljene štrcaljke.
A pink, biconvex, oval tablet, with the inscription “OL 20” on one side.
Ružičasta, bikonveksna, ovalna tableta s oznakom "OL 20" na jednoj strani.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3 – 14) uključivalo je ukupno 252 ambulantna bolesnika.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE; engl. mini mental state examination) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 − 14) included a total of 252 outpatients.
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3-14) included a total of 252 outpatients.
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer’s disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
U pivotalno ispitivanje monoterapije memantinom u liječenju blage do umjerene Alzheimerove bolesti (početne vrijednosti ukupnog MMSE od 10 do 22) bila su uključena 403 bolesnika.
A pivotal phase 3 randomized, crossover PK and PD study (which was also the first ever randomized study with immediate-release cysteamine bitartrate) demonstrated that at steady-state, patients receiving PROCYSBI every 12 hours (Q12H) maintained a comparable depletion of WBC cystine levels compared to immediate-release cysteamine bitartrate every 6 hours (Q6H).
Glavno randomizirano ispitivanje prelaženja faze 3 za FK (farmakokinetiku) i FD (farmakodinamiku) (koje je također prvo ikad randomizirano ispitivanje cisteamin bitartrata s trenutačnim oslobađanjem) pokazalo je da u stanju dinamičke ravnoteže ispitanici koji primaju PROCYSBI svakih 12 sati (Q12H) održavaju smanjenje razina cistina u leukocitima koje je usporedivo s onim cisteamin bitartrata s trenutačnim oslobađanjem svakih 6 sati (Q6H).
A pivotal phase 3, multi-centre, international, randomized, double-blind placebo-controlled study of single-agent sunitinib was conducted in patients with unresectable pNET.
Provedeno je pivotalno, multicentrično, međunarodno, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje faze III sunitiniba kao jedinog lijeka u bolesnika s neoperabilnim pNET-om.
A pivotal, randomised, double-blind, double-dummy, multinational Phase III study compared the efficacy, tolerability and safety of SANCUSO with that of 2 mg oral granisetron once daily in the prevention of nausea and vomiting in a total of 641 patients receiving multi-day chemotherapy.
U ključnom randomiziranom, dvostruko slijepom i dvostruko maskiranom multinacionalnom ispitivanju faze III, uspoređena je djelotvornost, podnošljivost i sigurnost lijeka SANCUSO i 2 mg granisetrona primijenjenog peroralno jedanput dnevno u prevenciji mučnine i povraćanja u ukupno 641 bolesnika koji su primali višednevnu kemoterapiju.
A pivotal, two-arm, randomised, open-label, phase II/III clinical trial in 258 patients with symptomatic malignant ascites due to EpCAM-positive carcinomas of whom 170 were randomised to catumaxomab treatment.
Pivotalno, randomizirano, otvoreno kliničko ispitivanje u fazama II/III s dvije skupine ispitanika obuhvatilo je 258 bolesnika sa simptomatskim malignim ascitesom uzrokovanim EpCAM pozitivnim karcinomima od kojih je 170 bolesnika randomizirano u skupinu liječenu katumaksomabom.
a PK parameters expressed as Geometric Mean (CV) except forT1/2, which is median. b PK parameters expressed as Arithmetic mean (SD)
a Farmakokinetički parametri izraženi kao geometrijska sredina (CV) osim za t½ koji je medijan vrijednosti.
A placebo-controlled 8-week trial of agomelatine 25-50mg/day in elderly depressed patients (≥ 65 years, N=222, of which 151 on agomelatine) demonstrated a statistically significant difference of 2.67 points on HAM-D total score, the primary outcome.
Placebom kontrolirano ispitivanje u trajanju od 8 tjedana agomelatina 25 – 50 mg/dan u starijih bolesnika s depresijom (≥ 65 godina, N= 222, od kojih je 151 liječen agomelatinom) pokazalo je statistički značajnu razliku od 2,67 bodova na HAM-D ukupnoj ljestvici, što je bio primarni ishod.
A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a sulphonylurea.
Provedeno je placebom kontrolirano ispitivanje u trajanju od 24 tjedna u svrhu ocjene djelotvornosti i sigurnosti linagliptina od 5 mg, u odnosu na placebo, kod bolesnika koji nisu dostatno liječeni kombinacijom metformina i sulfonilureje.
A placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with a thiazolidinedione (TZD) in patients with inadequate glycaemic control (HbA1c 7-10.5%) on TZD alone.
Placebom kontrolirano ispitivanje u trajanju od 24 tjedna provedeno je da bi se procijenila djelotvornost i sigurnost primjene saksagliptina u kombinaciji s tiazolidindionom (TZD) u bolesnika s neodgovarajućom kontrolom glikemije (HbA1c 7%–10,5%) koji su uzimali samo tiazolidindionom.
A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25 months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis.
Placebom kontrolirano ispitivanje u kojem je 89 odraslih bolesnika liječeno Enbrelom koji je dodan standardnoj terapiji (koja je uključivala ciklofosfamid ili metotreksat te glukokortikoide) s medijanom trajanja od 25 mjeseci nije pokazalo da je Enbrel učinkovit u liječenju Wegenerove granulomatoze.
A placebo-controlled trial, in which 89 adult patients were treated with etanercept in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25 months, has not shown etanercept to be an effective treatment for Wegener’s granulomatosis.
Placebom kontrolirano ispitivanje u kojem je 89 odraslih bolesnika liječeno etanerceptom koji je dodan standardnoj terapiji (koja je uključivala ciklofosfamid ili metotreksat te glukokortikoide) s medijanom trajanja od 25 mjeseci nije pokazalo da je etanercept učinkovit u liječenju Wegenerove granulomatoze.
A planned interim analysis of OS was conducted at the time of the PFS analysis and did not reach the interim boundary for statistical significance (HR=0.68 [0.51, 0.90], p=0.006).
Planirana interim analiza OS-a provedena je u vrijeme analize PFS-a i nije dosegla granicu statističke značajnosti (HR=0,68 [0,51; 0,90]; p=0,006).
a planned surgery (including dental) in the next seven days
planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
a planned surgery (including dental) in the next seven days.
planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
A planned surgical procedure within the next 30 days.
Kirurški postupak planiran u sljedećih 30 dana.
a plaque building up inside your arteries which could lead to heart attack and stroke;
tvaranje plakova na stjenkama arterija koje mogu dovesti do srčanog ili moždanog udara;
A plasma PAA to PAGN ratio exceeding 2.5 may indicate saturation of PAA to PAGN conversion capacity and the need for reduced dosing and/or increased frequency of dosing.
Omjer PAA i PAGN u plazmi koji prelazi 2,5 može ukazivati na zasićenje sposobnosti pretvorbe PAA u PAGN i potrebu za smanjenjem doze i/ili povećanjem učestalosti doziranja.
A plastic bottle containing 120 tablets and 2 pouches to keep the tablets dry.
Plastična bočica sadrži 120 tableta i 2 vrećice kako bi se tablete očuvale suhima.
A plastic bottle containing 120 tablets and 3 pouches to keep the tablets dry.
Plastična bočica sadrži 120 tableta i 3 vrećice kako bi se tablete očuvale suhima.
A plastic bottle containing 60 tablets and 3 pouches to keep the tablets dry.
Plastična bočica sadrži 60 tableta i 3 vrećice kako bi se tablete očuvale suhima.
A plastic measuring jug (in the medicine pack)
plastična odmjerna čašica (u pakiranju lijeka)
a platelet count > 1000 x 109/l or a history of thrombo-haemorrhagic events.
broj trombocita > 1000 x 109/l ili trombohemoragijski događaji u anamnezi.
A Plunger
A Klip
a Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination
a Plus pozadinski režim kombinacije fiksne doze emtricitabina 200 mg i tenofovirdizoproksil fumarata 300 mg
a Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination
a Plus pozadinski režim kombinacije fiksne doze emtricitabina 200 mg i tenofovirdizoproksilfumarata 300 mg
a Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination b Missing = excluded analysis
a Plus pozadinski režim kombinacije fiksne doze emtricitabina 200 mg i tenofovirdizoproksilfumarata 300 mg b Nedostaju = isključilo analizu
A polar fraction proposed to be serine derivatives accounted for approximately 20% in urine, but was detected only in small amounts (0-2%) in human plasma of some subjects.
Polarna frakcija za koju se pretpostavlja da pripada derivatima serina bila je zastupljena s oko 20% u mokraći, ali je u plazmi pojedinih ispitanika nađena samo u vrlo malim količinama (0–2%).
A polycarbonate Robertsite vial adaptor (allowing needleless luer connection to the vial).
Robertsite adapter za bočicu od polikarbonata (omogućuje priključenje na bočicu bez igle pomoću luer priključka).
A polystyrene resin/polyurethane carry case (shuttle) which can hold 3 tablets is included in each pack.
U svako pakiranje uključen je i priručni polistirenski/poliuretanski spremnik („shuttle“) za 3 kapsule.
A pooled analysis of five efficacy studies*, showed a 71.4% (95% CI:20.1;91.1) efficacy against severe rotavirus gastro-enteritis (Vesikari score 11) caused by rotavirus G2P[4] genotype during the first year of life.
Skupna analiza pet ispitivanja djelotvornosti*, pokazala je djelotvornost od 71,4% (95% CI:20,1;91,1) protiv teškog rotavirusnog gastroenteritisa (Vesikari rezultat 11) uzrokovanog rotavirusom genotipa G2P[4] tijekom prve godine života.
A pooled analysis of subjects with genotype 1 HCV infection, who were treated with ombitasvir, paritaprevir, and dasabuvir (a non-nucleotide NS5B inhibitor) with or without ribavirin in the Phase 2b and 3 clinical trials was conducted to explore the association between baseline NS3/4A, NS5A or NS5B substitutions/polymorphisms and treatment outcome in recommended regimens.
Analiza objedinjenih podataka prikupljenih u kliničkim ispitivanjima faze 2b i 3 u ispitanika s infekcijom HCV-om genotipa 1 liječenih ombitasvirom, paritaprevirom i dasabuvirom (nenukleotidni inhibitor NS5B), s ribavirinom (RBV) ili bez njega, provedena je kako bi se istražila povezanost između supstitucija/polimorfizama NS3/4A, NS5A ili NS5B prisutnih na početku ispitivanja i ishoda liječenja preporučenim režimima.
A pooled analysis of uncontrolled paediatric studies conducted in PAH with the bosentan 32 mg dispersible tablet formulation (FUTURE 1/2, FUTURE 3/Extension) included a total of 100 children treated with bosentan 2 mg/kg twice daily (n = 33), 2 mg/kg three times daily (n = 31), or 4 mg/kg twice daily (n = 36).
Analiza objedinjenih podataka iz nekontroliranih pedijatrijskih studija provedenih na oboljelima od PAH-a s 32 mg bosentana u obliku tablete za oralnu suspenziju (FUTURE 1/2, FUTURE 3/produžetak) uključila je ukupno 100 djece liječene bosentanom 2 mg/kg dvaput dnevno (n = 33), 2 mg/kg triput dnevno (n = 31) ili 4 mg/kg dvaput dnevno (n = 36).
A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator-controlled, double-blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration.
Provedena je analiza objedinjenih podataka o prijelomima kostiju kao nuspojavama u randomiziranim, usporednim lijekom kontroliranim, dvostruko slijepim kliničkim ispitivanjima u više od 8100 bolesnika u skupinama liječenima pioglitazonom i 7400 bolesnika u skupinama liječenima usporednim lijekom u trajanju do 3,5 godine.
a popping sound or sensation in an erect penis
pucketajući zvuk ili osjećaj u penisu u erekciji
A population analysis of the available data has found no evidence that patient weight affects olaparib plasma concentrations.
Populacijskom analizom dostupnih podataka nisu pronađeni dokazi da tjelesna težina bolesnice utječe na koncentracije olapariba u plazmi.